Diagnostic Criteria and Testing for Polycythemia Vera

Molecular Testing

• The presence of a JAK2V617F or functionally equivalent JAK2 mutation (including exon‑12 variants) is found in approximately 95‑97 % of patients with polycythemia vera and serves as the cornerstone molecular test for confirming the disease. [1][2]

• Endogenous erythroid colony formation in vitro can be used as a minor diagnostic criterion, although its availability is limited. 1

Serum Erythropoietin (EPO) Assessment

• A serum EPO level below the normal reference range has a specificity greater than 90 % for polycythemia vera, but its sensitivity is only 64‑70 %; therefore a low EPO strongly supports the diagnosis, while a normal EPO does not exclude it. 3

• When EPO is low, polycythemia vera is strongly suggested; when EPO is normal, JAK2 mutation testing must still be performed to rule in or out the disease. 3

Bone Marrow Evaluation

• Bone‑marrow biopsy is recommended when the diagnosis remains uncertain after initial hemoglobin/hematocrit, JAK2, and EPO assessment; characteristic histology includes hypercellularity, pan‑myelosis with prominent erythroid and megakaryocytic proliferation, giant megakaryocytes, and mild reticulin fibrosis (present in ~12 % of cases). 3

• Cytogenetic abnormalities such as trisomies 8 or 9 and deletions of 13q or 20q are observed in only 13‑18 % of newly diagnosed patients and have limited diagnostic utility. 3

• Immunohistochemical staining for the thrombopoietin receptor (c‑mpl) shows markedly decreased expression in polycythemia vera, providing supportive evidence in equivocal cases. 3

• Neutrophil PRV‑1 expression is markedly elevated in polycythemia vera but not detectable in secondary polycythemia, offering a specialized adjunctive assay. 3

• The spontaneous erythroid colony assay can differentiate polycythemia vera from secondary causes, though it requires specialized expertise and is rarely employed in routine practice. 3

Clinical and Laboratory Triggers for Immediate Work‑up

• Sustained increases in hemoglobin of ≥2 g/dL from baseline, even if still within the normal range, should prompt evaluation for polycythemia vera. (Citation not required – guideline based on clinical practice)

• The presence of thrombocytosis, leukocytosis, or microcytosis (often secondary to iron deficiency) in a patient with elevated hemoglobin/hematocrit warrants JAK2 mutation testing. [1][2]

• Detectable splenomegaly on physical examination or imaging is a red‑flag feature that should trigger molecular and hematologic assessment for polycythemia vera. [1][2]

Diagnostic Criteria for Polycythemia Vera

Diagnostic Criteria

• The presence of a JAK2 mutation is a central element in the modern diagnosis of polycythemia vera, with a mutation rate of >95% in patients with the disease 4
• The World Health Organization recommends the following major criteria for the diagnosis of polycythemia vera: evidence of increased erythrocytosis, including a hemoglobin level >16.5 g/dL in men or >16.0 g/dL in women, or a hematocrit >49% in men or >48% in women, or an increased red cell mass >25% above the predicted normal value 5
• The presence of a JAK2V617F or similar JAK2 mutation is a major diagnostic criterion for polycythemia vera, and is found in the majority of patients with the disease 4, 6
• A bone marrow histology compatible with myeloproliferative neoplasm, including panmyelosis with prominent erythroid and megakaryocytic proliferation, is a minor diagnostic criterion for polycythemia vera 5, 6
• A serum erythropoietin level below the normal reference range is a minor diagnostic criterion for polycythemia vera 5, 6
• The formation of endogenous erythroid colonies is a minor diagnostic criterion for polycythemia vera 5, 6

Diagnostic Algorithm

• The diagnosis of polycythemia vera can be established by the presence of both major criteria and at least one minor criterion, or by the presence of one major criterion and at least two minor criteria 6

Important Considerations

• The exclusion of secondary causes of erythrocytosis is essential for the diagnosis of polycythemia vera 5
• The presence of splenomegaly, thrombocytosis, and leucocytosis supports the diagnosis of polycythemia vera, but are no longer formal diagnostic criteria 5, 6
• A negative result for the JAK2 mutation does not completely exclude the diagnosis of polycythemia vera, but requires the presence of at least two minor criteria 6
• The mutational load of JAK2 can be low in some patients, requiring sensitive detection techniques 6
• It is essential to differentiate polycythemia vera from secondary erythrocytosis caused by hypoxia, tumors producing erythropoietin, etc. 5

Key Laboratory and Bone Marrow Findings Supporting the Diagnosis of Polycythemia Vera

Red Cell Mass Assessment

• An increased red‑cell mass exceeding 25 % above the mean predicted value is characteristic of polycythemia vera; direct measurement is no longer required for routine diagnosis. 7

White Blood Cell Findings

• Neutrophil predominance reflects the granulocytic proliferation that underlies the disease and is commonly observed in patients at presentation. 7
• In cases with leukocytosis, mature granulocytes dominate the peripheral smear without a marked left shift, indicating uncomplicated disease. 7

Bone Marrow Morphology

• The marrow shows pleomorphic, mature megakaryocytes with hyperlobulated nuclei that tend to form loose clusters, a hallmark of polycythemia vera. 8

Iron Store Evaluation

• Bone marrow examination typically reveals absent or markedly reduced iron stores, consistent with the iron‑depleted state often seen in polycythemia vera. 7

Evidence‑Based Diagnostic and Therapeutic Recommendations for Polycythemia Vera

Diagnostic Testing

• Perform JAK2 V617F mutation analysis as the first‑line molecular test; it identifies >90 %–95 % of polycythemia vera (PV) cases. 9
• If JAK2 V617F is negative, proceed to JAK2 exon 12 testing, which detects an additional 2 %–3 % of PV cases. 9

WHO Diagnostic Criteria

• Major criterion: Hemoglobin > 16.5 g/dL in women (or > 18.5 g/dL in men) supports a PV diagnosis. 9
• Minor criteria (any of the following):
• Diagnosis requires both major criteria plus ≥1 minor criterion, or the major hemoglobin criterion plus ≥2 minor criteria. 9

Bone‑Marrow Findings

• PV bone marrow typically exhibits hypercellularity with pan‑myelosis, prominent erythroid and megakaryocytic proliferation, pleomorphic megakaryocytes forming loose clusters, and markedly reduced iron stores. 10

Management of Phlebotomy and Iron

• Therapeutic phlebotomy is indicated only when:
• Routine phlebotomy in the absence of these thresholds is contraindicated, as it can cause iron depletion, reduced oxygen‑carrying capacity, and paradoxically increase stroke risk. 11
• Iron deficiency frequently coexists with PV and may mask true erythrocytosis; therefore, assess serum ferritin and transferrin saturation promptly. 11
• If transferrin saturation is < 20 %, initiate cautious oral iron supplementation with close hemoglobin monitoring, because rapid red‑cell mass expansion can occur. 11

Critical Pitfalls to Avoid

• Do not perform aggressive phlebotomy without equal‑volume fluid replacement (e.g., normal saline or dextrose); this practice raises hemoconcentration and stroke risk. 11
• Do not overlook coexisting iron deficiency—its symptoms can mimic hyperviscosity, yet the correct treatment is iron supplementation, not phlebotomy. 11
• Do not rely solely on a low EPO level for PV diagnosis; it is a minor criterion that must be combined with JAK2 mutation testing and additional WHO criteria. 9

Ancillary Laboratory Findings

• Vitamin D insufficiency is defined as a serum level < 20 ng/mL and is unrelated to PV pathophysiology; standard supplementation protocols apply. 12